Vomiting

MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study

Published in Surgery Litigation and Law Weekly, March 7th, 2008

MonoSol Rx, a drug delivery company specializing in dissolving thin film pharmaceutical products, announced that it has successfully completed a pilot clinical study for its thin film formulation of ondansetron, a selective 5-HT3 receptor antagonist used in the prevention and treatment of nausea and vomiting.

MonoSol Rx's thin film formulation of ondansetron was studied against GlaxoSmithKline's Zofran ODT(R) product. Based on the results of the study, MonoSol Rx is moving immediately to pivotal trials to enable drug submissions both in the US and Europe. The Company expects to file with the appropriate regulatory authorities in 2008.

A. Mark...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly

Source: Surgery Litigation and Law Weekly (2008-03-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry